Core Laboratories financials
$9.71−3.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $526.5M | $523.8M | $509.8M |
| Gross profit | $108.9M | $103.3M | $109.8M |
| Gross margin | 20.7% | 19.7% | 21.5% |
| Operating income | $56.5M | $58.6M | $54.6M |
| Net income | $29.7M | $31.4M | $36.7M |
| Net margin | 5.6% | 6.0% | 7.2% |
| Diluted EPS | $0.63 | $0.66 | $0.77 |
| EBITDA | $71.1M | $73.5M | $70.4M |
| Operating cash flow | $37.0M | $56.4M | $24.8M |
| Free cash flow | $22.4M | $43.4M | $14.2M |
| Diluted shares | 47.0M | 47.7M | 47.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $22.7M | $19.2M | $15.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $110.3M | $126.1M | $163.1M |
| Total assets | $584.0M | $585.1M | $586.4M |
| Total liabilities | $311.8M | $332.8M | $356.6M |
| Shareholders' equity | $272.2M | $252.3M | $229.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology